High Flow Nasal Cannula Oxygen During Sedation for Video-assisted Thoracoscopic Surgery

Chronic Obstructive Pulmonary Disease Clinical Trial

Official title:

Preventing Deoxygenation With High Flow Nasal Cannula Oxygen During Sedation for Video-assisted Thoracoscopic Surgery: A Randomized Controlled Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04520568
• Other study ID #: 0304712
• Status: Recruiting
• Phase: Phase 2
• Start date: August 1, 2020
• Est. completion date: December 1, 2020

Study information

• Verified date: August 2020
• Source: Alexandria University
• Contact: Rehab A. Abd Elaziz, Ass. Prof.
• Phone: 01001073703
• Email: trcium2002[@]yahoo.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

High-flow nasal cannula (HFNC) is a device that delivers10 to 70 L min-1 of heated, humidified 100% oxygen via nasal route. It provides positive airway pressure, decreases dyspnea, decreases the work of breathing, and improves comfort

Description:

Beneficial effects of the HFNC system have been assessed based on 3 physiologic conditions: decreased dead space, a high concentration of inspiratory oxygen, and positive pressure in the oro-laryngeal cavity.Studies have shown that it improves oxygenation in various perioperative settings such as the apneic patients, patients with respiratory failure , and patients undergoing bronchoscopy

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: December 1, 2020
• Est. primary completion date: November 10, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 30 Years to 70 Years

Eligibility

Inclusion Criteria:

• ASA physical status II and III,

• undergoing VATS

Exclusion Criteria:

• refusal of patients

• extrem of age

Related Conditions & MeSH terms

• Chronic Obstructive Pulmonary Disease
• Lung Diseases, Obstructive
• Pulmonary Disease, Chronic Obstructive
• Respiratory Failure
• Respiratory Insufficiency

Intervention

Combination Product:
• High flow nasal cannula
using sedation with the HFNC F&P AIRVOTM 2 to maintain oxygenation
• CONTROL
using general anaesthesia with one lung ventilation (OLV) technique

Locations

Country	Name	City	State
Egypt	Rehab Abd Elraof Abd Elaziz	Alexandria

Sponsors (1)

Lead Sponsor	Collaborator
Alexandria University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	arterial partial pressures of oxygen	an arterial blood sample will be taken after induction of anaesthesia then every 10 min till the end of the operation.	two hours
Primary	pH measurement	an arterial blood sample will be taken after induction of anaesthesia then every 10 min till the end of the operation.	two hours